Treatment of Mycosis Fungoides Tumor Stage
Introduction to Treatment Approaches
- The European Society for Medical Oncology recommends combined topical and systemic therapy, specifically PUVA combined with either interferon-alpha or systemic retinoids, with the addition of local radiotherapy for individual tumors, for mycosis fungoides in the nodular/tumor stage (stage IIB) 1, 2, 3
Treatment Algorithm for Tumor Stage MF
- For patients with one or few tumors, local radiotherapy alone may suffice as initial treatment, with a recommended radiation dose of 20-24 Gy for localized lesions, and low-dose radiotherapy (4-8 Gy) often sufficient for palliative treatment 3, 4, 5
- For patients with more extensive infiltrated plaques and tumors, combined modality therapy is preferred over monotherapy, with PUVA combined with interferon-alpha or systemic retinoids (including bexarotene) as standard or alternative combinations 1, 2, 3, 6
- Total skin electron beam therapy (TSEBT) can be considered, with doses of 30-36 Gy traditionally used, though lower doses (10-12 Gy) have been employed recently with fewer side effects and opportunity for re-treatment 3
Critical Treatment Principles
- The American Society of Clinical Oncology advises against aggressive polychemotherapy as initial therapy, as it is only justified for advanced disease with effaced lymph nodes or visceral involvement (stage IV), and does not improve overall survival in tumor-stage disease, causing serious side effects instead 1, 2, 5, 6
- Most patients with advanced disease die from secondary problems such as infections, which are worsened by cytotoxic drugs 1, 2, 6
Second-Line Options for Refractory Disease
- If skin-directed and combination therapies fail, gemcitabine may be considered, though responses are generally short-lived, and liposomal doxorubicin is an alternative single-agent option 3, 5
- Vorinostat (HDAC inhibitor) may be applied in advanced refractory disease 5
Important Caveats
- The National Comprehensive Cancer Network suggests that treatment goals should prioritize quality of life, aiming to achieve long-lasting remissions with drugs that can be safely used without long-term toxicity, considering that MF/SS patients are mostly of advanced age with many concomitant diseases 1, 2, 6
- Earlier therapeutic interventions may aggravate late-stage problems, as radiotherapy or phototherapy may contribute to mutations that increase tumor cell proliferative capacity 1, 2, 6
- A stage-adapted conservative approach is mandatory, with initial therapy being skin-directed, and systemic biological therapy added only if disease is not sufficiently controlled, and the treatment approach must be stage-adjusted and conservative for MF and its variants 1, 2, 3, 6
Allogeneic Stem Cell Transplantation
- For highly selected patients, in relatively young patients with refractory, progressive MF, allogeneic stem cell transplantation should be considered, though the optimal conditioning regimen and timing remain unknown 3